BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230403
DTEND;VALUE=DATE:20230406
DTSTAMP:20260516T053659
CREATED:20230125T100124Z
LAST-MODIFIED:20230125T100331Z
UID:36350-1680480000-1680739199@www.pharmajournalist.com
SUMMARY:4th TCR-based Therapies for Solid Tumors Summit
DESCRIPTION:The first TCR-based therapy approval in the US and Europe at the start of last year sparked a rush of excitement\, investment and collaborations. As further developers move into the clinic and some near commercialization\, it’s time for this community to unite to address the critical bottlenecks faced in development\, from discovery to approval\, to guarantee smooth sailing through the clinic. \nThe 4th TCR-based Therapies for Solid Tumors Summit is returning to Boston as the must-attend forum for TCR experts to come together to share industry updates and next generation engineered approaches to boost therapy safety and efficacy. \nJoin leaders and newcomers including Immunocore\, Medigene\, Immatics\, Captain T Cell and Anocca as they collaborate to guarantee tumor-specificity\, prevent cross-reactivity\, boost TCR and target discovery\, enhance solid tumor durability and explore TCR modalities. \nHuge milestones were achieved for the TCR field in 2022\, however\, there’s no time to sit back and relax. Collaborate with like-minded TCR trailblazers to secure clinical validation and streamline the road from discovery to commercialization. \nTo know more visit: https://ter.li/h6mn96
URL:https://www.pharmajournalist.com/event/4th-tcr-based-therapies-for-solid-tumors-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230411
DTEND;VALUE=DATE:20230414
DTSTAMP:20260516T053659
CREATED:20230216T110911Z
LAST-MODIFIED:20230216T110911Z
UID:36612-1681171200-1681430399@www.pharmajournalist.com
SUMMARY:3rd Annual Ligase Targeting Drug Development Summit
DESCRIPTION:Hijacking E3 Ligases to Mediate Degradation & Modulation of Undrugged Targets \nAs a family of over 600 known proteins\, ligases pose immense potential as viable avenues for harnessing previously undrugged targets. Key challenges remain however to rapidly discover and identify novel and underexploited ubiquitin E3s. Furthermore\, bottlenecks exist in the development of the established ligases; Cereblon and VHL. \n \nIt is now critical that we harness Cryo-EM\, X-Ray crystallography\, and other visualization tools to fully understand the structure and function of these lesser-known E3s\, accelerate ligand screening with new and improved tools\, leverage advances in DMPK knowledge to address concerns over toxicity in Cereblon\, propel VHL from ‘academic’ to clinic\, and all in\, de-risk the translation of candidate ligases to the clinic. \nThe 3rd Ligase Targeting Drug Development Summit is returning with fresh understanding and data from the forerunners of the field and those who have recently joined the space. Together we will investigate ligase structural and functional biology\, screening tools for optimal ligase\, linker\, and ligand identification\, explore tissue specificity\, uncover the key modalities where ligases can succeed\, and showcase the novel assays that are maximizing validation to ensure success in the clinic. \nThis dedicated forum will provide an unrivaled meeting point for industry leaders all under one specialized forum to strategically accelerate and de-risk the process of identifying\, validating\, and therapeutically leveraging cell and tissue-specific ubiquitin E3 ligases for degradation or modulation of targets in oncology\, immunology\, and beyond. \nTo know more: https://ter.li/gapgsb
URL:https://www.pharmajournalist.com/event/3rd-annual-ligase-targeting-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230417
DTEND;VALUE=DATE:20230420
DTSTAMP:20260516T053659
CREATED:20221215T130847Z
LAST-MODIFIED:20221215T130847Z
UID:36096-1681689600-1681948799@www.pharmajournalist.com
SUMMARY:2nd LNP Formulation & Process Development Summit
DESCRIPTION:Turbocharging Your Next Gen LNP End-To-End Development to Deliver Curative Promises to Patients \nFollowing exciting industry updates from Verve Therapeutics’ GalNAc-LNP for PCSK9 for HFpEF treatment\, to Recode’s 5th element\, the 2nd LNP Formulation & Process Development Summit is your must-attend meeting as this nanoparticle continues to dominate the biopharmaceutical industry in 2023. \nNew for 2023\, we have curated 3 streams of content for 2nd iteration of the summit: \n\nIn depth discussions divulging IP and regulatory compliance for LNP drug products\nMaximized LNP flexibility and versatility for payloads beyond mRNA vaccines with other RNA\, DNA\, gene therapy and gene editing possibilities\nLipid Chemistry & Discovery Track: Novel lipid discovery and particle engineering to customize LNP composition for next generation delivery vehicle\nFormulation & Process Development Track: Optimize your LNP development techniques for enhanced manufacturability and product quality\, and overcome stability issues of LNP-nucleic acid drug products\nLNP CMC & Manufacturing Track: Elevating your process control\, CQAs framework for CMC\, GMP compliance for seamless scale-up\n\nThis summit will offer the most comprehensive content and exclusive data\, equipping you with end-to-end LNP development journey to exploit this lucrative non-viral delivery vehicle for various payloads to your destined cells and organs. \nIn collaboration with Intellia Therapeutics\, Pfizer\, Sanofi\, ReCode Therapeutics\, Akagera Medicines\, the 2nd LNP Formulation & Process Development Summit is committed to serving you with their lessons learned to supercharge your pipeline and deliver curative promises to patients. \nJoin us to stay at the forefront of science\, network with 350+ LNP Biology\, Chemistry\, Formulation & Process Development\, Tech Ops & Manufacturing experts to gain competitive advantage to exploit LNP potentials! \nTo know more visit: https://ter.li/ol6e27
URL:https://www.pharmajournalist.com/event/2nd-lnp-formulation-process-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230418
DTEND;VALUE=DATE:20230421
DTSTAMP:20260516T053659
CREATED:20230119T091650Z
LAST-MODIFIED:20230119T091650Z
UID:36291-1681776000-1682035199@www.pharmajournalist.com
SUMMARY:3rd Fc Receptor Pathway Targeted Therapies 2023
DESCRIPTION:The field of FcRn receptor targeting is gaining ground-breaking speed as Argenx\, Janssen\, UCB and Immunovant compete to tackle myasthenia gravis and biopharma invest in transformative immunological therapy for autoimmune diseases as the next big drug opportunity. \nThe 3rd Fc Receptor Pathway Targeted Therapies Summit will once again feature unmissable conversations to advance targeting FcR and the subsequent generation of Fc manipulation since real-world proof and clinical value are now at the industry’s fingertips. \nJoin 100+ of your colleagues at the 3rd Fc Receptor Pathway Targeted Therapies Summit – from the fields of immunology\, antibody engineering\, pharmacology\, toxicology\, and immuno-oncology for three days of content that is unmatched in its scope\, all focused on the optimization of FcRn\, FcγR\, and novel Fc. \nPut your stake in the ground to revolutionise autoimmune illness and position yourself in front of the next wave of blockbuster drug development. \nTo know more visit: https://ter.li/y9vxt6
URL:https://www.pharmajournalist.com/event/3rd-fc-receptor-pathway-targeted-therapies-2023/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230418
DTEND;VALUE=DATE:20230421
DTSTAMP:20260516T053659
CREATED:20230127T095023Z
LAST-MODIFIED:20230127T095023Z
UID:36387-1681776000-1682035199@www.pharmajournalist.com
SUMMARY:mRNA Process Development & Manufacturing Europe
DESCRIPTION:mRNA therapeutics have catapulted into the limelight amidst the COVID-19 pandemic with multiple EMA approvals to help combat the virus. \nBringing together KOLs sharing case studies with actionable insights\, the inaugural mRNA Process Development & Manufacturing Summit Europe has been established as the first forum in Europe to support your in-house process development and manufacturing strategies. \nThe 3-day agenda has been carefully co-authored along with the leaders within the industry from the likes of BioNTech\, AstraZeneca and Genentech. A snapshot of key topics include: \n\nAssessing how dsRNA formation can be limited to reduce the purification requirements of the manufacturing process with BioNTech SE\nUncovering how to maximise biocomparability when scaling up the batch manufacturing process\, including identifying the critical process steps that introduce batch-to-batch variability with Genentech & Roche\nA snapshot of robust\, high-throughput online novel assays for identifying impurities with CureVac & AstraZeneca\nUnderstanding critical quality attributes and the differences in process development considerations for mRNA therapeutics and vaccines to achieve appropriate drug substance quality with the University of Sheffield & University Hospital Zurich\nHearing how the global market could function with a standard process platform to benefit all patients with Medicines Patent Pool\n\nThis is an opportunity to join 80+ mRNA enthusiasts from mRNA manufacturing\, analytics\, process development\, CMC\, quality control\, and drug substance to get key insights on scaling up mRNA drug substances in Europe whilst navigating mRNA process development and manufacturing regulatory guidelines to create commercially successful mRNA vaccines and therapeutics. \nTo know more visit: https://ter.li/f3ec38
URL:https://www.pharmajournalist.com/event/mrna-process-development-manufacturing-europe/
LOCATION:Sheraton Offenbach Hotel\, Am Buesing Palais\, Berliner Str. 111\,\, Offenbach am Main\, 63065\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230424
DTEND;VALUE=DATE:20230426
DTSTAMP:20260516T053659
CREATED:20230315T103819Z
LAST-MODIFIED:20230315T103819Z
UID:36830-1682294400-1682467199@www.pharmajournalist.com
SUMMARY:10th Annual Pre-Filled Syringes East Coast Conference
DESCRIPTION:10th Annual Pre-Filled Syringes East Coast Conference \nApril 24 – 25\, 2023 \nBoston\, USA \nDriving Innovations in Device Design\, Connectivity and Sustainability for Advanced Parenteral Combination Product \nhttps://www.pfsamericas.com/PJ-Event-listing \nThe 10th annual Pre-Filled Syringes East Coast conference will once again play host to an international audience of drug delivery\, medical device and PFS experts to discuss emerging trends and offer innovative solutions to the challenges facing the pre-filled syringes industry\, helping attendees to secure global success for their devices. \nThe past year has seen significant developments in the injectables landscape with the evolving regulatory landscape\, accelerating opportunities in digitilization and simulation to improve device design efficiency\, and increased opportunities for connectivity to improve the user experience. \nFurthermore\, with a growing need for circular economy\, this year’s conference will assess case studies of sustainable approaches for device packaging and life cycle management\, while panel discussions\, FDA and BioPhorum addresses will evaluate current and upcoming combination product guidelines and the potential for harmonization. \nAs part of SAE Media Group’s leading drug delivery portfolio of events\, this event will bring you the key insights you need to expand and enhance your injectable device portfolio and the opportunity to network with senior players throughout the industry.  \nBenefits of Attending: \n\nDiscover the latest industry developments for improved large volume and high viscous delivery via advanced autoinjector and on body delivery system design\nAssess the growing opportunities of digitalization and simulation for improved device development efficiency and potential\nEngage in an FDA regulatory roundup from the office of combination products\, insights into EPR identification from BioPhorum and a panel discussion assessing harmonization of the regulatory landscape\nDelve into emerging technologies in injectable device design and case studies on digital integration of medical devices for improved user experience\n\nBenchmark against sustainable device packaging case studies driving the combination product industry towards circular economy
URL:https://www.pharmajournalist.com/event/10th-annual-pre-filled-syringes-east-coast-conference/
LOCATION:Boston\, USA
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260516T053659
CREATED:20230126T191447Z
LAST-MODIFIED:20230126T191447Z
UID:36382-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:Next Generation Cardiovascular Drug Development Summit
DESCRIPTION:Welcome to the Next Generation Cardiovascular Drug Development Summit \nExecuting Cell & Gene Therapy for Cardiac Regeneration \nFollowing technology advancements and the surge of investment in developing the next generation of cardiovascular disease drugs\, the opportunity to successfully leverage our knowledge of CRISPR/Cas9\, siRNA\, autologous iPSC therapy\, capsid engineering\, and digital medicine to reduce the soaring fatality rate has never been closer. \nThe Next Generation Cardiovascular Drug Development Summit in Boston is the only industry-led summit committed to overcoming preclinical challenges to advance your ischemic heart disease\, arrhythmogenic cardiomyopathy\, strokes and hypertension pipelines. \nTo know more visit: https://ter.li/s7qk9l
URL:https://www.pharmajournalist.com/event/next-generation-cardiovascular-drug-development-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260516T053659
CREATED:20230202T105002Z
LAST-MODIFIED:20230324T110700Z
UID:36448-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:5th Cell Engager Summit
DESCRIPTION:The 5th Annual Cell Engager Summit is back in Boston\, MA this year – the only industry-led meeting bringing together 100+ pharma and biotech leaders will assemble for a 3-day agenda including 4 unique pre-conference workshops to delve into the biggest challenges cell engager therapeutics face. Breaking into the solid tumor\, preventing CRS and maximizing the quality of insights we gain from preclinical modeling. \nFor unmissable opportunities\, including: \n\nGain first-hand knowledge of the difficulties of developing kinase inhibitors to improve selectivity\, cross the blood-brain barrier\, and combat resistance\nUtilize cutting-edge platforms and technologies to maximise target validation and precisely predict off-target impacts to save time and costs\nEstablish long-lasting relationships by speaking with top pharma and biotech firms that are working on kinase inhibitor medicines and looking for the best-in-class solutions directly\n\nJoin your colleagues from the likes of Apexigen\, Regeneron Pharmaceuticals\, Genentech\, Roche\, Amgen\, Boehringer Ingelheim and many more at the most comprehensive cell engager event\, leaving no stone unturned\, this highly focussed meeting covers everything translational and clinical in greater depth and detail than any before it. \nDownload the full event guide for your sneak peek.
URL:https://www.pharmajournalist.com/event/5th-cell-engager-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260516T053659
CREATED:20230202T110212Z
LAST-MODIFIED:20230202T110212Z
UID:36461-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:5th Neuroimmunology Drug Development Summit
DESCRIPTION:With increasing prioritization for neuroscience discovery\, huge biopharma is investing in expanding its departments\, focusing on glial biology\, neuroinflammatory biomarkers\, and optimizing various approaches to target the likes of LRKK2\, TREM2\, and more. Therefore\, there is a great amount of novel and promising research to be discussed in 2023. \nUniting 100+ neuroinflammation and neuroimmunology experts across all neurological indications\, including AD\, PD\, ALS\, and MS\, the 5th Annual Neuroimmunology Drug Development meeting will return to Boston to host discovery\, preclinical\, translational\, and clinical experts from the likes of Genentech\, Muna Therapeutics\, Biogen\, Janssen\, Bristol Myers Squibb\, Sanofi\, Takeda\, and Roche. \nWith new speakers from the hottest biopharma in neuroimmunology delivering\, a comprehensive program of pioneering and cutting-edge content\, don’t miss your crucial chance to join this niche audience of innovators with a shared desire to explore strategy\, creation\, and implementation of research\, biomarker\, and clinical hypothesis testing in neuroimmunology. \nTo know more visit: https://ter.li/w642sd
URL:https://www.pharmajournalist.com/event/5th-neuroimmunology-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:Info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260516T053659
CREATED:20230207T094958Z
LAST-MODIFIED:20230207T094958Z
UID:36542-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:Gene Therapy Durability Summit
DESCRIPTION:Uniting the leading minds in gene therapy at the Gene Therapy Durability Summit\, join us to: \n\nLeverage knowledge from current clinical trials with relevant durability data across a range of indication types using AAV\nBetter understand what can be extrapolated and how to gain confidence in the data collected\nBuild study designs with durability in mind and explore how well preclinical models have predicted clinical durability to date\n\nHear from the likes of Pfizer\, Selecta Biosciences\, Spark Therapeutics\, Rocket Pharmaceuticals\, ASC Therapeutics and more across a preconference workshop day\, expert presentations\, interactive panel discussions\, dedicated Q&A time and highly appraised networking opportunities to meet and learn from the leaders of this pioneering field. \nWhen you attend you will: \n\nUnderstand the regulatory requirements to determine robust durability\nExplore the challenges short term immunogenicity has on durability\nNavigate how to overcome long term immunogenicity concerns on durability\nOptimize vectors constructs to maximize gene therapy durability\nDiscover how to better predict the translational success of durability when progressing from preclinical to clinical trials\n\nRegister to attend with your colleagues and get up to 20% off your tickets – https://ter.li/oeczu3
URL:https://www.pharmajournalist.com/event/gene-therapy-durability-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260516T053659
CREATED:20230227T130914Z
LAST-MODIFIED:20230227T130914Z
UID:36686-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:2nd ADC Analytical Development Summit 2023
DESCRIPTION:The 2nd ADC Analytical Development Summit (April 25-27\, 2023 | Boston\, MA) is the only meeting focused on optimizing the application of analytical technologies for ADC\, from drug-linker and drug substance through to drug product to guide regulatory specifications and submissions\, to enhance understanding of your drug and to exert control over your process. \nSee the complete 2023 event guide here. \nWith many new ADCs under development\, the analytical challenges are only increasing as the existing hurdles keep changing\, with the regulatory guidance still being limited. This is a unique touch point for drug developers to discuss the core analytical challenges the industry is facing including drug linkers\, drug substances\, drug formulation\, and drug products. \nYou and your team can expect to leave this meeting equipped to have a deeper understanding of your drug and confidently enter conversations with regulators with thought-provoking insights from our expert speaker faculty including: \n\nYuan Gao\, Head of Analytical Development\, ADC Therapeutics \nJessica Webb\, Scientist\, Analytical Sciences\, AstraZeneca\nGuifeng Jiang\, Head of Analytical Development Pharmaceutical Operation\, Bolt Biotherapeutics\nThomas Gardinier\, Head of Materials Analysis\, Elucida Oncology\nSimon Letarte\, Director\, Gilead\nAdrienne Wildt\, Senior Director of Analytical Development\, ImmunoGen\nShuwen Sun\, Principal Scientist\, Merck & Co\nVimal Patel\, Vice President\, Head of CMC & Supply Chain\, Orum Therapeutics\nJulie Beaudet\, CMC Staff Scientist\, Regeneron Pharmaceuticals\nSarah Owen\, Senior Scientist Potency Assays\, Seagen\nMelvin Flores\, Director Quality Control Analytical & Microbiology\, Sutro Biopharma\nMay Zhu\, Director of Analytical Development- External Interface Management\, Takeda\n\nJoin them here. \nWith 100+ attendees\, 4+ hours of dedicated networking\, and 3 days of exciting new content\, including a pre-conference focus day on comparability studies\, this is a conversation you won’t want to miss to hopefully\, increase knowledge on your ADC quality attributes to understand and strive for regulatory approval
URL:https://www.pharmajournalist.com/event/2nd-adc-analytical-development-summit-2023/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230426
DTEND;VALUE=DATE:20230428
DTSTAMP:20260516T053659
CREATED:20230126T113838Z
LAST-MODIFIED:20230310T095341Z
UID:36359-1682467200-1682639999@www.pharmajournalist.com
SUMMARY:6th Annual Pharmaceutical Microbiology USA Conference
DESCRIPTION:6th Annual Pharmaceutical Microbiology USA Conference\nApril 26 – 27\, 2023 \nBoston\, MA\, USA \nhttp://www.pharma-microbiology-usa.com/PharmaJournalistWL \nSponsored by: LONZA \nChaired by: Donald Singer\, USP General Chapter Committee Microbiology Chair\, US Pharmacopeia  \nContamination Control and Microbial Methods Explored to Assure Product Quality and Prevention \nMicrobiology remains an essential tool in reducing microbial growth in the manufacture of pharmaceuticals\, to detect and eliminate microorganisms that would pose a risk to patients and jeopardise product batches. \nEnsuring the sterility of the finished product continues to be one of the most critical aspects of drug development\, however an array of factors is also sustaining new growth and transformation in this field. The regulatory landscape is changing\, firstly with the preparation of Annex I\, in addition to increasing requirements pertaining to data integrity. Light is being shed on recent product recalls for mould contamination\, and infection outbreaks serve as a reminder to pay more attention to these overlooked organisms\, as well as considerations towards container closure integrity testing which is being increasingly deployed to block microbe movement. \nOn top of this\, the developing integration of automation and robotics into the manufacturing pipeline\, as well as the increased need for more rapid microbiology methods brought about in part by the surge in ATMPs\, are all highlighting the necessity of the field in Pharma. \nThis industry is ever expanding\, join our leading experts at the 6th Annual Pharmaceutical Microbiology East Coast Conference in Boston\, USA to discuss and analyse the latest advances and challenges surrounding Pharmaceutical Microbiology. Network with the  industry professionals\, discuss revisions in regulatory and guidance documents\, and gain a deeper insights. \nEvent Hashtag: #MicrobiologyUSA  \nKey Conference Highlights: \n\nReview implementation guidance and validation for efficient microbial testing programs\nUncover how to implement effective contamination control for manufacturing and the impact throughout pharmaceutical microbiology\nLearn how to control mold contamination and apply risk-based tools to tackle recovery\nDelve into the role the microbiologist plays in bioburden assessments and holistic closure integrity testing for new drug modalities\nUnderstand innovative techniques to control contamination as it relates to cell therapy products\, combination\, and traditional microbiological drug products\n\nView the full agenda: http://www.pharma-microbiology-usa.com/PharmaJournalistWL
URL:https://www.pharmajournalist.com/event/6th-annual-pharmaceutical-microbiology-usa-conference/
LOCATION:Boston\, MA\, USA
ORGANIZER;CN="SAE Media Group":MAILTO:lamprini.balasi@saemediagroup.com
END:VEVENT
END:VCALENDAR